Direct stimulatory effects of the TLR2/6 ligand bacterial lipopeptide MALP-2 on neutrophil granulocytes.
Bacterial lipopeptides represent a group of bacterial compounds able to trigger the functions of cells of the innate immune response. Whereas diacylated lipopeptides are recognized by TLR2/6 dimers, triacylated lipopeptides were shown to act via TLR2/1 dimers. Although several previous studies dealt with the effect of the TLR2/1 ligand Pam(3)CysSK(4) on neutrophil granulocytes (PMN), it is still not clear whether TLR2/6 ligand lipopeptides can directly influence PMN functions. In the present study we used highly purified human neutrophils to investigate the direct effects of the diacylated mycoplasmal macrophage activating lipopeptide-2 (MALP-2) on the function of neutrophil granulocytes. After exposure to 10 ng/ml MALP-2 neutrophils acquired activated cell shape, secreted IL-8 and MIP-1beta and their phagocytic capacity was enhanced. Analysis of cell surface activation markers confirmed the activating effect of MALP-2, the expression of CD62L was downregulated whereas CD11b was upregulated on PMN after exposure to MALP-2. The constitutive apoptosis of PMN was inhibited after exposure to MALP-2. However, MALP-2 exerted only a short-term effect on the apoptosis of resting neutrophils, a longer lasting effect was observed after transendothelial migration. MALP-2 did not directly induce the production of reactive oxygen intermediates but primed PMN for a fMLP-induced oxidative burst. The migration of neutrophils was enhanced after treatment with MALP-2. This was due, however, to a chemokinetic rather than to a chemotactic effect. Pam(3)CysSK(4) also activated PMN, but in comparison to MALP-2, at higher concentrations. These findings suggest that diacylated lipopeptides are important microbial structures recognized by and acting on neutrophil granulocytes.
Wilde
Inga
I
Institute of Medical Microbiology and Hygiene, University of Luebeck, Ratzeburger Allee 160, 23538 Lubeck, Germany.
Lotz
Sonja
S
Engelmann
David
D
Starke
Andrea
A
van Zandbergen
Ger
G
Solbach
Werner
W
Laskay
Tamás
T
D017209:Apoptosis / Q000502:physiology; D016207:Cytokines / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007113:Immunity, Innate; D055666:Lipopeptides; D018375:Neutrophil Activation / Q000187:drug effects* / Q000276:immunology; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism*; D009842:Oligopeptides / Q000276:immunology / Q000378:metabolism*; D010587:Phagocytosis / Q000276:immunology; D016897:Respiratory Burst / Q000502:physiology; D051195:Toll-Like Receptor 2 / Q000276:immunology / Q000378:metabolism*; D051216:Toll-Like Receptor 6 / Q000276:immunology / Q000378:metabolism*
D016207:Cytokines; D055666:Lipopeptides; D009842:Oligopeptides; D051195:Toll-Like Receptor 2; D051216:Toll-Like Receptor 6; C106335:macrophage stimulatory lipopeptide 2